youtube_live
Q3 2026 earnings • in 1 day
See detailschevron_right
CRL:NYSE
Charles River Laboratories Intrtnl, Inc.
$338.54
arrow_downward
-5.88%(-21.14) 1D
$337.00
arrow_downward
-0.45% (-1.54)bedtimeAfter hours
Closed: Nov 2, 4:00:04 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CRL...
Open
$368.42
High
$369.61
Low
$337.37
Mkt. cap
16.16B
Avg. vol.
1.13M
Volume
1.62M
52-wk high
$379.63
52-wk low
$146.20
EPS
-$4.85
Beta
1.40
Shares outstanding
47.74M
No. of employees
19K
Open
$368.42
High
$369.61
Low
$337.37
Mkt. cap
16.16B
Avg. vol.
1.13M
Volume
1.62M
52-wk high
$379.63
52-wk low
$146.20
EPS
-$4.85
Beta
1.40
Shares outstanding
47.74M
No. of employees
19K
News stories
From web sources and news partners
FinancialContent
·
2 hours ago
What to expect from Charles River Laboratories’s (CRL) Q3 earnings
GuruFocus
·
4 hours ago
Charles River Laboratories International Inc (CRL) Shares Fall 5.8% -- What GF Score of 64 Tells Investors
News Corp
·
7 hours ago
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors
Zacks
·
13 hours ago
Charles River's Q3 Earnings on Deck: What's in Store for the Stock?
Profile
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients.
Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
About Charles River Laboratories Intrtnl, Inc.
CEO-
Employees19K
Founded1947
HeadquartersWilmington, Massachusetts, United States
SectorHealth care
Websitecriver.com
Analyst ratings
Based on 15 analysts giving stock ratings to CRL in the past 3 months
Strong buy
Buy
14
Hold
1
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for CRL in the last 3 months.
Highest
Current $338.54
$357.00 (+5.45%)
Average
$329.85 (-2.57%)
Lowest
$295.00 (-12.86%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Casey Woodring J.P. Morgan | Buy | Maintained | $345.00 | +1.9% | 10/16/2026 |
Kallum Titchmarsh Morgan Stanley | Buy | Reiterated | $340.00 | +0.4% | 10/13/2026 |
Ryan Halsted RBC Capital | Buy | Maintained | $322.00 | -4.9% | 10/06/2026 |
Kevin Caliendo UBS | Buy | Initiated | $357.00 | +5.5% | 09/30/2026 |
Michael Ryskin Bank of America Securities | Buy | Reiterated | - | - | 09/28/2026 |
David Windley Jefferies | Buy | Maintained | $340.00 | +0.4% | 09/28/2026 |
Justin Bowers Deutsche Bank | Buy | Reiterated | $320.00 | -5.5% | 09/25/2026 |
Elizabeth Anderson CFA Evercore ISI | Buy | Maintained | $330.00 | -2.5% | 09/25/2026 |
Ann Hynes Mizuho Securities | Hold | Maintained | $295.00 | -12.9% | 09/25/2026 |
Eric Coldwell Robert W. Baird | Buy | Maintained | $334.00 | -1.3% | 09/25/2026 |
Luke Sergott Barclays | Buy | Maintained | $330.00 | -2.5% | 09/24/2026 |
Charles Rhyee TD Cowen | Buy | Reiterated | $325.00 | -4% | 09/25/2026 |
Jared Haase William Blair | Buy | Reiterated | - | - | 09/24/2026 |
Unknown Analyst Stephens | Buy | Initiated | $320.00 | -5.5% | 09/22/2026 |
David Toung Argus Research | Buy | Reiterated | $330.00 | -2.5% | 09/16/2026 |
Michael Luo CFA CLSA | Hold | Downgraded | $219.00 | -35.3% | 07/20/2026 |
Patrick B Donnelly Citi | Buy | Maintained | $265.00 | -21.7% | 07/08/2026 |
Max Smock William Blair | Buy | Maintained | - | - | 06/02/2026 |
Charles Weston RBC Capital | Buy | Initiated | $215.00 | -36.5% | 04/13/2026 |
Dan Leonard UBS | Hold | Maintained | $175.00 | -48.3% | 02/25/2026 |
Next call in 32:11:57
Wed, Nov 4, 9:00 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $2.97
Revenue / Est. (USD)
- / 960.36M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.00B | 994.23M | 995.83M | 1.00B |
Cost of goods sold | 652.72M | 665.36M | 672.79M | 625.06M |
Cost of revenue | 652.72M | 665.36M | 672.79M | 625.06M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 173.64M | 192.02M | 149.12M | 214.18M |
Operating expense | 201.05M | 284.04M | 164.46M | 227.27M |
Total operating expenses | 853.77M | 949.40M | 837.25M | 852.33M |
Operating income | 151.08M | 44.83M | 158.58M | 151.74M |
Other non operating income | -22.62M | 27.72M | -123.11M | 25.99M |
EBT including unusual items | 87.20M | -294.10M | -29.94M | 53.17M |
EBT excluding unusual items | 104.48M | 35.18M | 8.62M | 148.43M |
Income tax expense | 31.64M | -17.81M | -15.14M | 53.93M |
Effective tax rate | 36.29% | 6.06% | 50.56% | 101.43% |
Other operating expenses | - | - | - | - |
Net income | 54.42M | -276.56M | -14.84M | -1.48M |
Net profit margin | 5.42% | -27.82% | -1.49% | -0.15% |
Earnings per share | 2.43 | 2.39 | 2.06 | 3.02 |
Interest and investment income | 1.42M | 1.02M | 1.03M | 1.03M |
Interest expense | -25.40M | -23.78M | -26.74M | -30.34M |
Net interest expenses | -23.98M | -22.76M | -25.71M | -29.31M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 236.25M | 169.61M | 225.73M | 217.54M |
Gain or loss from assets sale | - | - | 117.98M | 24.92M |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events